IGC Pharma, Inc. Common Stock (IGC)

August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

August 14, 2026 — Investor attention continues to focus on microcap stocks, small-cap earnings, artificial intelligence, cybersecurity, biotechnology, Alzheimer’s drug development and high-growth technology, with Kartoon Studios (NYSE: TOON), Cycurion (NASDAQ: CYCU), SurgePays (NASDAQ: SURG), MDxHealth (NASDAQ: MDXH) and IGC Pharma (NYSE: IGC) presenting several developing catalysts.

August 14, 2026 - VivoSim Labs, Inc. (NASDAQ: VIVS) is emerging at the intersection of artificial intelligence, biotechnology, drug development, 3D human tissue models and New Approach Methodologies (NAMs) as pharmaceutical companies face increasing pressure to identify costly drug toxicity problems earlier in the development process.

Aug. 14, 2026 — Kartoon Studios, Inc. (NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.

Aug. 13, 2026 — Kartoon Studios, Inc. (NYSE: TOON) has signed an agreement with Amazon Prime Video (NASDAQ: AMZN) to stream its animated series HUNDRED ACRE WOOD, based on A.A. Milne’s Winnie-the-Pooh, beginning February 18, 2027 . Amazon will support the launch with prominent “Hero Banners,” while its “Shop the Show” program will enable viewers to purchase products featuring HUNDRED ACRE WOOD characters while streaming the series.

Aug. 11, 2026 – Sub-$1 stocks, microcap stocks and emerging growth companies are drawing investor attention as fresh catalysts develop across health and wellness, military drones, defense communications, artificial intelligence, Alzheimer's biotechnology, data centers and entertainment . Companies in focus include Planet Green Holdings Corp. (NYSE: PLAG), Peraso Inc. (NASDAQ: PRSO), Linkage Global Inc. (NASDAQ: UZX), IGC Pharma, Inc. (NYSE: IGC), Fort Technology Inc. (NASDAQ: FRTT) (TSXV: FORT), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Kartoon Studios, Inc. (NYSE: TOON).

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026.

Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies

Aug. 5, 2026 – Investors continue scanning the sub-$1 market for companies generating significant news flow, strategic developments, and potential turnaround opportunities. Among the names attracting attention are Reitar Logtech Ltd. (NASDAQ: RITR), IGC Pharma, Inc. (NYSE American: IGC), Bluejay Diagnostics, Inc. (NASDAQ: BJDX), and C3is Inc. (NASDAQ: CISS), while several OTC companies are also drawing increased interest.

Microcap stocks continue attracting investor attention as companies across nuclear energy, defense communications, biotechnology, and entertainment announce developments that could shape their next phase of growth. Among the companies making news are Mangoceuticals, Inc. (NASDAQ: MGRX), Peraso Inc. (NASDAQ: PRSO), IGC Pharma, Inc. (NYSE: IGC), and Kustom Entertainment, Inc. (NASDAQ: KUST) .

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that it is evaluating potential civil remedies following the federal jury verdict in United States v. Andrew Left, No. 2:24-CR-456, in the United States District Court for the Central District of California.

As investors continue searching for overlooked opportunities across Artificial Intelligence (AI), biotechnology , shipping , digital infrastructure , online businesses , and entertainment , several undervalued listed companies on the NYSE and NASDAQ are entering catalyst-rich periods supported by clinical milestones, regulatory progress, strategic transactions, expanding balance sheets, and shareholder-focused initiatives trading for pennies on the dollar. Among those drawing increased attention are IGC Pharma (NYSE: IGC), C3is Inc. (NASDAQ: CISS), Gossamer Bio (NASDAQ: GOSS), KIDZ AI Inc. (NASDAQ: KIDZ), Onfolio Holdings, Inc. (NASDAQ: ONFO), and Kartoon Studios, Inc. (NYSE: TOON).

Sponsored Programming Airs Across Bloomberg Television U.S., MENA, and Latin America, Supported by Television Commercials From Lantern Pharma, Datavault AI, Big Sky Industrial, FreeCast, PetVivo Holdings, and IGC Pharma

Artificial Intelligence is rapidly transforming drug discovery, clinical research , and Alzheimer's disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront of that evolution. The clinical-stage biotechnology company will present seven scientific papers at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12-15, highlighting a growing portfolio of AI-powered healthcare technologies designed to accelerate Alzheimer's drug development , improve clinical trials , and enhance precision medicine .

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development

Investors following the rapidly growing Alzheimer's disease, Artificial Intelligence (AI) , and biotechnology sectors now have an opportunity to hear directly from IGC Pharma, Inc. (NYSE American: IGC) CEO Ram Mukunda in a new interview on The Street Reports Podcast , where he discusses the Company's clinical progress, AI initiatives, and long-term strategy.

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing Alzheimer's disease therapeutics and AI-enabled healthcare technologies, disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions.

Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) continues to build momentum as the company expands production, secures new commercial partnerships, and advances the commercialization of its graphene technology platform. Founder and CEO Craig Nicol recently appeared on CEO.CA to discuss GMG's growing ability to manufacture and sell its expanding portfolio of graphene-based products. Watch the interview Now!

As investors continue searching for the next generation of multibagger opportunities, several companies trading near or under the $1 level are capturing attention through major developments across Artificial Intelligence (AI), autonomous aviation, defense technology, digital infrastructure, battery storage, and Alzheimer's drug development.

Investors searching for the next generation of micro-cap growth stocks are increasingly focusing on companies with exposure to some of today's fastest-growing sectors, including Artificial Intelligence (AI), Alzheimer's drug development , Healthcare Technology , Defense Technology , Renewable Energy , Electric Vehicles (EVs) , Military Drones , and Digital Infrastructure .

IGC Pharma, Inc. (NYSE: IGC) a clinical-stage Biotechnology company developing treatments for Alzheimer's Disease and Artificial Intelligence (AI) enabled healthcare technologies, today announced the beta release of its proprietary Agentic Harmonization Assistant ("AHA"), a patent-pending Healthcare AI platform designed to accelerate Alzheimer's Drug Discovery, Clinical Research , Precision Medicine , and Pharmaceutical Development by helping researchers quickly combine and organize Alzheimer's disease , aging-related, and other medical data that is often scattered across multiple databases, studies, hospitals, clinical trials, healthcare systems, and research institutions.

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American: IGC), Medicus Pharma (NASDAQ: MDCX), and NRx Pharmaceuticals (NASDAQ: NRXP)